Feedback / Questions
MEDI-3617 - AstraZeneca
AstraZeneca: Q3 FY 2016 Results
(AstraZeneca)
-
Nov 12, 2016 -
Discontinuation in solid tumors due to safety/efficacy reason
Discontinued
•
Oncology
https://www.astrazeneca.com/content/dam/az/press-releases/2016/20161110%20Q3%202016%20Rslts%20prss%20(FINAL).v2.pdf
Nov 12, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious